- Home
- BTG vs GH Comparison
BTG vs GH Comparison
Compare BTG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTG
- GH
- Stock Information
- Founded
- BTG 2006
- GH 2011
- Country
- BTG Canada
- GH United States
- Employees
- BTG N/A
- GH N/A
- Industry
- BTG Precious Metals
- GH Medical Specialities
- Sector
- BTG Basic Materials
- GH Health Care
- Exchange
- BTG Nasdaq
- GH Nasdaq
- Market Cap
- BTG 5.5B
- GH 4.9B
- IPO Year
- BTG N/A
- GH 2018
- Fundamental
- Price
- BTG $4.34
- GH $57.19
- Analyst Decision
- BTG Buy
- GH Strong Buy
- Analyst Count
- BTG 3
- GH 17
- Target Price
- BTG $4.25
- GH $58.24
- AVG Volume (30 Days)
- BTG 38.9M
- GH 2.3M
- Earning Date
- BTG 11-05-2025
- GH 11-05-2025
- Dividend Yield
- BTG 2.31%
- GH N/A
- EPS Growth
- BTG N/A
- GH N/A
- EPS
- BTG N/A
- GH N/A
- Revenue
- BTG $2,172,330,000.00
- GH $828,849,000.00
- Revenue This Year
- BTG $66.93
- GH $28.07
- Revenue Next Year
- BTG $6.87
- GH $21.61
- P/E Ratio
- BTG N/A
- GH N/A
- Revenue Growth
- BTG 11.75
- GH 28.74
- 52 Week Low
- BTG $2.20
- GH $20.14
- 52 Week High
- BTG $4.60
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- BTG 61.47
- GH 48.85
- Support Level
- BTG $4.19
- GH $53.40
- Resistance Level
- BTG $4.60
- GH $61.95
- Average True Range (ATR)
- BTG 0.16
- GH 2.52
- MACD
- BTG 0.00
- GH -1.24
- Stochastic Oscillator
- BTG 55.93
- GH 25.96
About BTG B2Gold Corp Common shares (Canada)
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.